Tag - EDSA

Developments

FDA clears Edesa’s IND for Phase 2 vitiligo study

Edesa Biotech (NASDAQ: EDSA) has announced that the FDA has cleared the company’s Investigational New Drug (IND) application for its Phase 2 clinical study of EB06 in vitiligo, enabling Edesa to expand recruitment...

October 15, 2026

Markets

Brookline starts Edesa Biotech at buy; PT $10

Brookline Capital Markets launched coverage of Edesa Biotech (NASDAQ:EDSA) with a “buy” rating and $10 price target. The stock closed at $2.16 on March 27. Edesa is developing EB01, a topical sPLA2 inhibitor that...

March 30, 2020

Tag - EDSA

FDA clears Edesa’s IND for Phase 2 vitiligo study

Brookline starts Edesa Biotech at buy; PT $10

Subscribe